Pro Dex Inc: Form 10-Q for the period ended Mar 31, 2021
Filed with the SEC on May 6, 2021 and accepted by EDGAR at May 6, 2021, 16:00 ET.
Management's discussion and analysis
As filed, 32,852 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis should be read in conjunction with our unaudited interim condensed financial statements and the related notes and other financial information appearing elsewhere in this report.
COMPANY OVERVIEW
The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of the results of operations and financial condition of Pro-Dex, Inc. (“Company,” “Pro-Dex,” “we,” “our,” or “us”) for the three-month and nine-month periods ended March 31, 2021 and 2020. This discussion should be read in conjunction with the condensed financial statements and the notes thereto included elsewhere in this report. This report contains certain forward-looking statements and information. The cautionary statements included herein should be read as being applicable to all related forward-looking statements wherever they may appear. Our actual future results could differ materially from those discussed herein.
Except for the historical information contained herein, the matters discussed in this report, including, but not limited to, discussions of our product development plans, business strategies, strategic opportunities and market factors influencing our results, including uncertainties related to the COVID-19 pandemic, are forward-looking statements that involve certain risks and uncertainties. Actual results may differ from those anticipated by us as a result of various factors, both foreseen and unforeseen, including, but not limited to, our ability to continue to develop new products and increase sales in markets characterized by rapid technological evolution, the impact of the COVID-19 pandemic on our suppliers, customers, and us, consolidation within our target marketplace and among our competitors, competition from larger, better capitalized competitors, and our ability to realize returns on opportunities. Many other economic, competitive, governmental, and technological factors could impact our ability to achieve our goals. You are urged to review the risks, uncertainties, and other cautionary language described in this report, as well as in our other public disclosures and reports filed with the Securities and Exchange Commission (“SEC”) from time to time, including, but not limited to, the risks, uncertainties, and other cautionary language discussed in our Annual Report on Form 10-K for our fiscal year ended June 30, 2020.
We specialize in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial (“CMF”) markets. We have patented adaptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. We also manufacture and sell rotary air motors to a wide range of industries.
Our principal headquarters are located at 2361 McGaw Avenue, Irvine, California 92614 and our phone number is (949) 769-3200. Our Internet address is www.pro-dex.com (http://www.pro-dex.com). Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, amendments to those reports and other SEC filings are available free of charge through our website as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC. In addition, our Code of Ethics and other corporate governance documents may be found on our website at the Internet address set forth above. Our filings with the SEC may also be read and copied at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov (http://www.sec.gov) and company specific information at www.sec.gov/edgar/searchedgar/companysearch.html (http://www.sec.gov/edgar/searchedgar/companysearch.html).
Basis of Presentation
The condensed results of operations presented in this report are not audited and those results are not necessarily indicative of the results to be expected for the entirety of the fiscal year ending June 30, 2021, or any other interim period during such fiscal year. Our fiscal year ends on June 30 and our fiscal quarters end on September 30, December 31, and March 31. Unless otherwise stated, all dates refer to our fiscal year and those fiscal quarters.
Critical Accounting Estimates and Judgments
Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States. The preparation of our financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. We base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used or changes in the accounting estimate that are reasonably likely to occur could materially change the financial statements. Management believes that there have been no significant changes during the three and nine months ended March 31, 2021 to the items that we disclosed as our critical accounting policies in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020.
Business Strategy and Future Plans
Our business today is almost entirely driven by sales of our medical devices. Many of our significant customers place purchase orders for specific products that were developed under various development and/or supply agreements. Our customers may request that we design and manufacture a custom surgical device or they may hire us as a contract manufacturer to manufacture a product of their own design. In either case, we have extensive experience with autoclavable, battery-powered and electric, multi-function surgical drivers and shavers. We continue to focus a significant percentage of our time and resources on providing outstanding products and service to our valued principal customers. During the first quarter of fiscal 2021, our largest customer executed an amendment to our existing supply agreement such that we shall continue to supply their surgical handpieces to them through calendar 2025.
Simultaneously, we are working to build top-line sales through active proposals of new medical device products with new and existing customers. Our patented adaptive torque-limiting software has been very well received in the CMF market and we have continued investment in this area with research and development focused on applying this technology most recently to thoracic surgical applications, and we launched our first thoracic driver in the third quarter of fiscal 2020. Additionally, we have other significant engineering projects under way described more fully in results of operations.
Additionally, as previously disclosed, on November 6, 2020, we purchased an approximate 25,000 square foot industrial building in Tustin, California (the “Franklin Property”). This building is located approximately four miles from our Irvine, California headquarters and was acquired to provide us additional capacity for our expected continued future growth. Currently, we are continuing with our build-out of the property and have yet to transition any of our employees into the facility. We anticipate that upon completion of initial improvements, we will be able to execute on Phase I of our plan, which includes, among other things, the installation of a clean room to enable us to expand our capacity for the manufacture of batteries and new products. We expect that we will begin operations in the new facility some time during the first quarter of next fiscal year.
In summary, our current objectives are focused primarily on maintaining our relationships with our current medical device customers, investing in research and development activities to design Pro-Dex branded drivers to leverage our torque-limiting software, expand our manufacturing capacity through the build-out of the Franklin Property, and promoting active product development proposals to new and existing customers for both orthopedic shavers and screw drivers for a multitude of surgical applications, and other medical devices, while monitoring closely the progress of all these individual endeavors. Our research and development and general and administrative expenses have, in recent periods, increased disproportionately to our growth in revenue as we focus on new product development and we anticipate this to continue in the near term. These expenditures are being made in an effort to release new products and garner new customer relationships. While we expect revenue growth in the future, it may not be a consistent trajectory, but rather periods of incremental growth that current expenditures are helping to create. However, there can be no assurance that we will be successful in any of these objectives.
COVID-19 Pandemic
We have adjusted certain policies and procedures based on applicable national, state, and local emergency orders and safety guidance that may be issued from time to time, in order to effectively manage our business during the pandemic, including:
- Non-essential employees that are able to work remotely are doing so;
- Increased frequency of disinfectant cleanings, especially for high-touch surfaces;
- Curtailed business travel;
- Multiple, staggered work shifts have been implemented in order to achieve effective social distancing;
- Provided training, education and appropriate personal protective equipment;
- Implemented quarterly, now monthly, company-wide COVID-19 testing; and
- Daily temperature screenings and personal affidavits of wellness.
While we have yet to see any decline in our customer orders, we have received and accepted some customer requests to delay the shipment of their existing orders. We provide our largest customer with a device used primarily in elective surgeries and although this customer has not requested a reduction or delay to their planned shipments, if this pandemic continues to adversely impact the United States and other markets where our products are sold, coupled with the recommended deferrals of elective procedures by governments and other authorities, we would expect to see a decline in demand from our principal customer.
We are focused on the health and safety of all those we serve – our customers, our communities, our employees, and our suppliers. We are supporting our customers according to their priorities and working with them to the degree that we can offer relief in the form of delayed shipments. We are focused on continuity of supply by working with our suppliers.
While the COVID-19 pandemic did not materially adversely affect our financial results and business operations thus far, economic and health conditions in the United States and across much of the globe have changed rapidly since March 2020, and we cannot predict the full impact of the COVID-19 pandemic on our business.
Description of Business Operations
Revenue
The majority of our revenue is derived from designing, developing and manufacturing surgical devices for the medical device industry. The proportion of total sales by type is as follows (in thousands, except percentages):
| Net Sales: | Three Months Ended March 31, 2021 | % of Revenue | 2020 | % of Revenue | Nine Months Ended March 31, 2021 | % of Revenue | 2020 | % of Revenue |
|---|---|---|---|---|---|---|---|---|
| Medical device products | $10,645 | 91% | $6,656 | 78% | $23,757 | 83% | $18,148 | 76% |
| Industrial and scientific | 208 | 2% | 140 | 2% | 593 | 2% | 485 | 2% |
| Dental and component | 24 | — | 91 | 1% | 98 | 1% | 185 | 1% |
| NRE & Proto-type | 55 | — | 190 | 2% | 185 | — | 457 | 2% |
| Repairs and other | 807 | 7% | 1,431 | 17% | 3,961 | 14% | 4,435 | 19% |
| $11,739 | 100% | $8,508 | 100% | $28,594 | 100% | $23,710 | 100% |
17
Certain of our medical device products utilize proprietary designs developed by us under exclusive development and supply agreements. All of our medical device products utilize proprietary manufacturing methods and know-how, and are manufactured in our Irvine, California facility, as are our industrial products. Details of our medical device sales by type is as follows (in thousands, except percentages):
| Medical device sales: | Three Months Ended March 31, 2021 | % of Total | 2020 | % of Total | Nine Months Ended March 31, 2021 | % of Total | 2020 | % of Total |
|---|---|---|---|---|---|---|---|---|
| Orthopedic | $4,534 | 43% | $4,027 | 61% | $12,664 | 53% | $12,628 | 70% |
| CMF | 2,066 | 19% | 1,143 | 17% | 4,661 | 20% | 4,034 | 22% |
| Thoracic | 4,045 | 38% | 1,486 | 22% | 6,432 | 27% | 1,486 | 8% |
| Total | $10,645 | 100% | $6,656 | 100% | $23,757 | 100% | $18,148 | 100% |
Sales of our medical device products increased $4.0 million, or 60%, and $5.6 million, or 31%, for the three and nine months ended March 31, 2021, compared to the corresponding periods of the prior fiscal year. Our medical device revenue to our largest customer, included in orthopedic sales above, increased $615,000 and $563,000, respectively, for the three and nine months ended March 31, 2021 compared to the corresponding periods of the prior fiscal year, due to volume increases offset by contractual price concessions. Our thoracic sales revenue increased $2.6 million and $4.9 million for the three and nine months ended March 31, 2021, compared to the corresponding periods of the prior fiscal year. As previously discussed, we completed the private-label effort for our thoracic driver and launched initial shipments in the amount of $1.5 million to our customer in the third quarter of fiscal 2020. The increase in thoracic revenue during fiscal 2021, represents additional follow-on orders from that customer. Additionally, recurring revenue from distributors of CMF drivers increased $923,000 and $627,000, respectively, for the three and nine months ended March 31, 2021, compared to the corresponding periods of the prior fiscal year and includes $220,000 of revenue from our latest CMF driver, which we sell to our existing largest customer under a distribution agreement executed earlier this fiscal year.
Sales of our compact pneumatic air motors, reported as industrial and scientific sales above, increased $68,000, or 49%, and $108,000, or 22%, respectively, for the three and nine months ended March 31, 2021, compared to the corresponding periods of the prior fiscal year. The revenue increase relates to a continued interest in these legacy products but is not due to any substantive marketing efforts.
Sales of our dental products and components declined for the three and nine months ended March 31, 2021, compared to the corresponding periods of the prior fiscal year and we expect future declines in this area as we are no longer manufacturing dental products, but rather are simply selling remaining component inventory. As previously discussed, in January 2018, we sent notification to our dental product customers that we were discontinuing the manufacture of these products. The cessation of our dental line of products did not have a material impact on our financial position or results of operations and reflected a conscious decision to increase capacity for our medical device products.
Repair revenue decreased $624,000, or 44%, and $474,000, or 11%, for the three and nine months ended March 31, 2021, respectively, compared to the corresponding periods of the prior fiscal year due to decreased repairs of the orthopedic handpiece we sell to our largest customer. We expect repair revenue to continue to decrease based upon a downward trend we have seen in the volume of repairs of this orthopedic handpiece.
At March 31, 2021, we had a backlog of approximately $11.6 million, of which $7.9 million is scheduled to be delivered in the fourth quarter of fiscal 2021 and the balance is scheduled to be delivered next fiscal year. Our backlog represents firm purchase orders received and acknowledged from our customers and does not include all revenue expected to be generated from existing customer contracts. We may experience variability in our new order bookings due to various reasons, including, but not limited to, the timing of major new product launches and customer planned inventory builds. However, we do not typically experience seasonal fluctuations in our shipments and revenues.
Cost of Sales and Gross Margin
(in thousands except percentages)
| Cost of sales: | Three Months Ended March 31, 2021 | % of Total | 2020 | % of Total | Nine Months Ended March 31, 2021 | % of Total | 2020 | % of Total |
|---|---|---|---|---|---|---|---|---|
| Product cost | $7,000 | 95% | $5,284 | 99% | $17,120 | 94% | $14,781 | 99% |
| Under(over)-absorption of manufacturing costs | 118 | 2% | (53) | — | 470 | 3% | (51) | — |
| Inventory and warranty charges | 236 | 3% | 67 | 1% | 548 | 3% | 125 | 1% |
| Total cost of sales | $7,354 | 100% | $5,298 | 100% | $18,138 | 100% | $14,855 | 100% |
| Three Months Ended March 31, 2021 | 2020 | Nine Months Ended March 31, 2021 | 2020 | Year over Year ppt Change Three Months | Nine Months | |
|---|---|---|---|---|---|---|
| Gross margin | 37% | 38% | 37% | 37% | (1) | — |
Cost of sales for the three months ended March 31, 2021, increased $2.1 million, or 39%, compared to the corresponding period of the prior fiscal year. The increase in total costs of sales was caused by the 38% increase in revenue for the same period. Under-absorption of manufacturing costs increased by $171,000 for the three months ended March 31, 2021, compared to the corresponding period of the prior fiscal year due in part to COVID-19 related absences. We have incurred paid absences in our machine shop, assembly and quality operations that reduce our ability to absorb our fixed costs because total production hours are reduced. Costs relating to inventory and warranty charges increased $169,000 for the third quarter ended March 31, 2021 compared to the third quarter of the prior fiscal year.
Gross profit increased by approximately $1.2 million, or 37%, for the three months ended March 31, 2021, compared to the corresponding period of the prior fiscal year, consistent with the overall increase in revenue. Gross margin as a percentage of sales decreased by approximately 1 percentage point compared to the corresponding period of the prior fiscal year due primarily to the increases in inventory and warranty charges, which often increase in periods of high product development.
Cost of sales for the nine months ended March 31, 2021 increased by $3.3 million, or 22%, compared to the corresponding period of the prior fiscal year, consistent with the increased revenue of 21% for the same period, the reasons for which are discussed above. Additionally, total cost of sales reflects a $521,000 increase in under-absorbed manufacturing costs due to reduced production hours resulting in part from paid absences related to COVID-19. Inventory and warranty charges increased by approximately $423,000, or 338%, for the nine months ended March 31, 2021, compared to the corresponding period of the prior fiscal year, due to increased scrap and inventory charges in the amount of $152,000 and increased warranty expenses of $271,000. Both inventory and warranty related expenses tend to increase in periods of higher volume sales and in periods with higher product development activity.
Gross profit increased by $1.6 million, or 18%, for the nine months ended March 31, 2021, compared to the corresponding period of the prior fiscal year, primarily as a result of the increase in revenue discussed above. Gross margin for the nine months ended March 31, 2021, remained flat, at 37%, compared to the corresponding period of the prior fiscal year.
Operating Expenses
Operating Costs and Expenses
(in thousands except % change)
| Operating expenses: | Three Months Ended March 31, 2021 | % of Net Sales | 2020 | % of Net Sales | Nine Months Ended March 31, 2021 | % of Net Sales | 2020 | % of Net Sales | Year over Year % Change Three Months | Nine Months |
|---|---|---|---|---|---|---|---|---|---|---|
| Selling expenses | $136 | 1% | $161 | 2% | $415 | 2% | $438 | 2% | (16%) | (5%) |
| General and administrative expenses | 1,280 | 11% | 725 | 9% | 2,922 | 10% | 2,052 | 9% | 77% | 42% |
| Research and development costs | 1,104 | 10% | 620 | 7% | 3,184 | 11% | 1,501 | 6% | 78% | 112% |
| $2,520 | 22% | $1,506 | 18% | $6,521 | 23% | $3,991 | 17% | 67% | 63% |
Selling expenses consist of salaries and other personnel-related expenses for our business development department, as well as advertising and marketing expenses, and travel and related costs incurred in generating and maintaining our customer relationships. Selling expenses for the three and nine months ended March 31, 2021, decreased $25,000, or 16%, and $23,000, or 5%, respectively, compared to the corresponding periods of fiscal 2020. These decreases relate primarily to reduced bonus compensation and reduced travel expenses due to the COVID-19 pandemic.
General and administrative expenses (“G&A”) consists of salaries and other personnel-related expenses of our accounting, finance and human resource personnel, as well as costs for outsourced information technology services, professional fees, directors’ fees, and other costs and expenses attributable to being a public company. G&A increased $555,000 and $870,000, respectively, during the three and nine months ended March 31, 2021, when compared to the corresponding periods of the prior fiscal year. The increases relate primarily to higher stock compensation expense related to the stock options awarded in the current fiscal year, relocation and operating expenses of the Franklin Property, increased legal fees related to intellectual property matters and our debt refinancing in combination with our Property Loan, increased personnel-related expenses including bonus accruals, as well as higher insurance expense.
Research and development costs generally consist of salaries, employer-paid benefits, and other personnel- related costs of our engineering and support personnel, as well as allocated facility and information technology costs, professional and consulting fees, patent-related fees, lab costs, materials, and travel and related costs incurred in the development and support of our products. Research and development costs for the three and nine months ended March 31, 2021, increased $484,000 and $1.7 million, respectively, compared to the corresponding periods of the prior fiscal year. These increases are primarily due to increased personnel-related expense and increased spending on internal development projects.
Although the majority of our research and development costs relate to sustaining activities related to products we currently manufacture and sell, we have created a product roadmap to develop future products. The research and development costs represent between 38% and 49% of total operating expenses for all periods presented and are expected to increase in the future as we continue to invest in the business. The amount spent on projects under development is summarized below (in thousands):
| Three and Nine Months Ended March 31, 2021 | Three and Nine Months Ended March 31, 2020 | Market Launch (1) | Est Annual Revenue | |||
|---|---|---|---|---|---|---|
| Total Research & Development costs: | $1,104 | $3,184 | $620 | $1,501 | ||
| Products in development: | ||||||
| ENT Shaver | 192 | 450 | 136 | 291 | Q4 2021 | $1,000 |
| Vital Ventilator | 26 | 91 | — | — | Q1 2022 | $1,500 |
| CMF Driver | 263 | 731 | 60 | 106 | (2) | $1,000 |
| Sustaining & Other | 623 | 1,912 | 424 | 1,104 | ||
| Total | $1,104 | $3,184 | $620 | $1,501 |
(1) Represents the calendar quarter of expected market launch.
(2) The CMF Driver was completed in the third quarter of fiscal 2021 and shipped to our existing largest customer under a distribution agreement we executed in the first quarter of fiscal 2021. We generated revenue of $220,000 related to these initial shipments during the third quarter ended March 31, 2021. This project is now complete and future engineering expenses related to this project will be included in sustaining and other.
20
Interest & Other Income
Interest income for the three and nine months ended March 31, 2021 and 2020, includes interest and dividends from our money market accounts and investment portfolio. During the nine months ended March 31, 2020, we also recorded $17,000 of miscellaneous income related to cash collected related to note receivable extensions granted on a note we previously wrote off.
Interest Expense
Interest expense consists primarily of interest expense related to the notes payable described more fully in Note 9 to the condensed consolidated financial statements contained elsewhere in this report.
Gain on Sale of Investments
During the quarter ended March 31, 2021, we sold several of the stocks in our portfolio of equity investments receiving proceeds of $2.9 million and recording a gain on the sale in the amount of $783,000. During the quarter ended September 30, 2020, we liquidated two of the stocks in our portfolio of equity investments, receiving proceeds of $115,000 and recording a gain on the sale in the amount of $12,000.
Income Tax Expense
The effective tax rate for the three and nine months ended March 31, 2021 and 2020, is slightly less than our combined expected federal and applicable state corporate income tax rates due to federal and state research credits, as well as a tax benefit recognized as a result of common stock awarded to employees under previously granted performance awards in the first quarter of fiscal 2021 as described more fully in Note 7 to the condensed consolidated financial statements contained elsewhere in this report.
Liquidity and Capital Resources
Cash and cash equivalents at March 31, 2021, decreased $2.5 million to $3.9 million as compared to $6.4 million at June 30, 2020. The following table includes a summary of our condensed statements of cash flows contained elsewhere in this report.
(in thousands)
| Cash provided by (used in): | As of and For the Nine Months Ended March 31, 2021 | 2020 |
|---|---|---|
| Operating activities | $(2,803) | $2,298 |
| Investing activities | $(4,375) | $(2,253) |
| Financing activities | $4,631 | $(3,409) |
| Cash and Working Capital: | ||
| Cash and cash equivalents | $3,874 | $4,378 |
| Working Capital | $20,091 | $16,140 |
Operating Activities
Net cash used in operating activities was $2.8 million for the nine months ended March 31, 2021, primarily due to net income of $3.6 million and non-cash deprecation and amortization of $502,000 and share-based compensation of $508,000 offset by an increase in accounts receivable in the amount of $6.8 million due to our largest customer changing their payment terms from net 30 to net 90 in conjunction with a contract extension. Additionally, our net income included $795,000 of realized gains from the sales of stock in our marketable securities portfolio.
Net cash provided by operating activities was $2.3 million for the nine months ended March 31, 2020, primarily due to net income of $3.6 million and non-cash depreciation and amortization of $426,000. Our inventory increased by $2.4 million primarily related to the thoracic driver that we began shipping during our third quarter ended March 31, 2020, as well as another customer CMF driver under development, which launched in the third quarter ended March 31, 2021.
Investing Activities
Net cash used in investing activities for the nine months ended March 31, 2021, was $4.4 million and related primarily to the purchase of the Franklin Property acquired during the second quarter of fiscal 2021 for a purchase price of $6.5 million as well as expenditures related to machinery and equipment totaling $872,000. Offsetting these uses of cash, we sold some of our marketable securities during the nine months ended March 31, 2021 for $3.0 million.
Net cash used in investing activities for the nine months ended March 31, 2020, was $2.3 million and related to investments in marketable equity securities of publicly traded companies in the amount of $1.8 million and purchases of machinery and equipment in the amount of $422,000.
Financing Activities
Net cash provided by financing activities for the nine months ended March 31, 2021, totaled $4.6 million and included $9.1 million in various loans from Minnesota Bank and Trust (“MBT”) more fully described in Note 9 to the condensed consolidated financial statements contained elsewhere in this report, offset by $4.0 million related to the repurchase of 161,291 shares of our common stock pursuant to our share repurchase program, $307,000 of principal payments on our loans with MBT, as well as payment of $259,000 of employee payroll taxes related to the award of 40,000 shares of common stock to employees under previously granted performance awards.
Net cash used in financing activities for the nine months ended March 31, 2020, totaled $3.4 million and related primarily to the $3.0 million repurchase of 204,921 shares of our common stock pursuant to our share repurchase program as well as $471,000 of principal payments on our term loan from MBT more fully described in Note 9 to the condensed consolidated financial statements contained elsewhere in this report.
Financing Facilities & Liquidity Requirements for the next twelve months
As of March 31, 2021, our working capital was $20.0 million. We currently believe that our existing cash and cash equivalent balances together with our accounts receivable balances will provide us sufficient funds to satisfy our cash requirements as our business is currently conducted for at least the next 12 months. In addition to our cash and cash equivalent balances, we expect to derive a portion of our liquidity from our cash flows from operations. We may also borrow against our $2.0 million Revolving Loan with MBT (See Note 9 to condensed consolidated financial statements contained elsewhere in this report).
We are focused on preserving our cash balances by monitoring expenses, identifying cost savings, and investing only in those development programs and products that we believe will most likely contribute to our profitability. As we execute on our current strategy, however, we may require debt and/or equity capital to fund our working capital needs and requirements for capital equipment to support our manufacturing and inspection processes. In particular, we have experienced negative operating cash flow in the past, especially as we procure long-lead time materials to satisfy our backlog, which can be subject to extensive variability. We believe that if we need to raise additional capital to fund our operations we can do so by selling additional shares of our common stock under the ATM Agreement.
Investment Strategy
We invest surplus cash from time to time through our Investment Committee, which is comprised of one management director, Mr. Van Kirk, and two non-management directors, Mr. Cabillot and Mr. Swenson, who chairs the committee. Both Mr. Cabillot and Mr. Swenson are active investors with extensive portfolio management expertise. We leverage the experience of these committee members to make investment decisions for the investment of our surplus operating capital or borrowed funds. Additionally, many of our securities holdings include stocks of public companies that either Messrs. Swenson or Cabillot or both may own from time to time either individually or through the investment funds that they manage, or other companies whose boards they sit on. The Investment Committee approved each of the investments comprising the $4.1 million of marketable public equity securities held at March 31, 2021.
Controls and procedures
As filed, 3,806 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our Chief Executive Officer and Chief Financial Officer (the principal executive officer and principal financial officer, respectively) conducted an evaluation of the design and operation of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)). The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
In accordance with SEC rules, an evaluation was performed under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer of the effectiveness, as of March 31, 2021, of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). “Internal control over financial reporting” includes those policies and procedures that:
(1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the issuer;
(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management and directors of the issuer; and
(3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the issuer’s assets that could have a material effect on the financial statements.
Based on that evaluation as of March 31, 2021, our Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures are effective.
Internal Control over Financial Reporting
During the three months ended March 31, 2021, there were no changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.
Inherent Limitations on the Effectiveness of Controls
In designing and evaluating our disclosure controls and procedures, our management recognized that any system of controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Risk factors
As filed, 2,743 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our business, future financial condition and results of operations are subject to a number of factors, risks and uncertainties, which are disclosed in Item 1A, entitled “Risk Factors” in Part I of our Annual Report on Form 10-K for our fiscal year ended June 30, 2020, as well as any amendments thereto or additions and changes thereto contained in this quarterly report on Form 10-Q for the quarter ended March 31, 2021. Additional information regarding some of those risks and uncertainties is contained in the notes to the condensed consolidated financial statements included elsewhere in this report and in Item 2, entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part I of this report. The risks and uncertainties disclosed in our Form 10-K, our quarterly reports on Form 10-Q and other reports filed with the SEC are not necessarily all of the risks and uncertainties that may affect our business, financial condition and results of operations in the future.
There have been no material changes to the risk factors as disclosed in our annual report on Form 10-K for the fiscal year ended June 30, 2020, except as provided in any amendments thereto and those set forth below.
Borrowings that we made under our credit facility with MBT in the third quarter of fiscal 2021 make it more difficult to satisfy various financial covenants under that credit facility, and a breach of those financial covenants could have a material adverse effect on our business.
The amended credit agreement that we entered into with MBT in the second quarter of fiscal 2021 contains various covenants, including, among other covenants, a quarterly fixed charge coverage ratio and debt service coverage ratio. As discussed elsewhere in this report, during the third quarter of fiscal 2021, we borrowed an additional $4,000,000 under the MBT credit facility ($3,000,000 under the Term Note A and $1,000,000 under the Term Note B). These additional borrowings make it more difficult for us to satisfy the facility’s quarterly fixed charge coverage ratio and debt service coverage ratio. As disclosed in Item 1A “Risk Factors” in Part I of our Annual Report on Form 10-K for our fiscal year ended June 30, 2020, a breach of any of the covenants or restrictions under our debt obligations could result in a default under those obligations and the lender could proceed against us and our assets that serve as collateral for the debt. We could also be forced to take remedial actions such as restructuring or refinancing our debt, seeking additional debt or equity capital, reducing or delaying our business activities, or selling assets. There can be no assurance that any such measures would be successful.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-01-01 to 2021-03-31 | $11.7m | us-gaap:Revenues |
| Revenue | 9 months2020-07-01 to 2021-03-31 | $28.6m | us-gaap:Revenues |
| Cost of revenue | 3 months2021-01-01 to 2021-03-31 | $7.4m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2020-07-01 to 2021-03-31 | $18.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2021-01-01 to 2021-03-31 | $4.4m | us-gaap:GrossProfit |
| Gross profit | 9 months2020-07-01 to 2021-03-31 | $10.5m | us-gaap:GrossProfit |
| Research and development | 3 months2021-01-01 to 2021-03-31 | $1.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-07-01 to 2021-03-31 | $3.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-01-01 to 2021-03-31 | $1.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-07-01 to 2021-03-31 | $3.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-01-01 to 2021-03-31 | $102.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2020-07-01 to 2021-03-31 | $231.0k | us-gaap:InterestExpense |
| Income tax | 3 months2021-01-01 to 2021-03-31 | $592.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-07-01 to 2021-03-31 | $1.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-01-01 to 2021-03-31 | $2.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-07-01 to 2021-03-31 | $3.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-01-01 to 2021-03-31 | $0.50 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2020-07-01 to 2021-03-31 | $0.90 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-01-01 to 2021-03-31 | $0.52 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2020-07-01 to 2021-03-31 | $0.94 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-01-01 to 2021-03-31 | 3,966,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2020-07-01 to 2021-03-31 | 3,998,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2020-07-01 to 2021-03-31 | −$2.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 9 months2020-07-01 to 2021-03-31 | $4.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2021-03-31 | $3.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-03-31 | $26.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-03-31 | $42.3m | us-gaap:Assets |
| Current liabilities | At period end2021-03-31 | $6.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-03-31 | $21.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-03-31 | $20.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001553350-21-000335. Last ingested by Listed: Oct 30, 2026, 16:16 ET. Listed shows no prices and gives no investment advice.